CryoLife (CRY) Earning Somewhat Favorable Media Coverage, Analysis Finds
Press coverage about CryoLife (NYSE:CRY) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. CryoLife earned a daily sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the medical equipment provider an impact score of 46.192062889438 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- 12% of CAGR by 2022 Will Cancer Diagnostics Market Period of Growth (emailwire.com)
- Global Heart Valve Devices Market forecast 2017-2025 detailed in new research report by Credence Research (digitaljournal.com)
- Aortic Valve Replacement Market Projected to Discern Stable Expansion During 2016 – 2024 (reports.pr-inside.com)
- Reviewing West Pharmaceutical Services (WST) & CryoLife (CRY) (americanbankingnews.com)
- CryoLife: Good Opportunity To Buy One Of The Better Small-Cap Stocks In The Med Tech Space (seekingalpha.com)
Shares of CryoLife (NYSE CRY) opened at $19.55 on Thursday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 4.90 and a current ratio of 5.96. The stock has a market capitalization of $665.80, a PE ratio of 48.54 and a beta of 0.82. CryoLife has a twelve month low of $14.02 and a twelve month high of $24.00.
Several analysts have issued reports on the company. Northland Securities restated a “buy” rating and set a $23.50 price objective on shares of CryoLife in a report on Monday, November 13th. TheStreet downgraded CryoLife from a “b” rating to a “c+” rating in a report on Monday, October 30th. Zacks Investment Research downgraded CryoLife from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. Lake Street Capital boosted their price objective on CryoLife to $26.00 and gave the stock a “buy” rating in a report on Wednesday, October 11th. Finally, Canaccord Genuity restated a “buy” rating and set a $25.00 price objective on shares of CryoLife in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $23.63.
TRADEMARK VIOLATION NOTICE: “CryoLife (CRY) Earning Somewhat Favorable Media Coverage, Analysis Finds” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/23/cryolife-cry-earning-somewhat-favorable-media-coverage-analysis-finds.html.
In other news, CEO James P. Mackin sold 125,000 shares of the company’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total value of $2,751,250.00. Following the transaction, the chief executive officer now owns 398,399 shares in the company, valued at approximately $8,768,761.99. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David Ashley Lee sold 33,190 shares of the company’s stock in a transaction dated Wednesday, November 8th. The shares were sold at an average price of $19.00, for a total value of $630,610.00. Following the completion of the transaction, the chief financial officer now owns 324,339 shares in the company, valued at approximately $6,162,441. The disclosure for this sale can be found here. Insiders sold a total of 229,240 shares of company stock worth $4,888,065 in the last quarter. 6.00% of the stock is owned by corporate insiders.
CryoLife Company Profile
CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.
Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.